First-line immune checkpoint inhibitors in low programmed death-ligand 1-expressing population
Introduction: Inhibitors of programmed cell death 1 (PD1) and its ligand (PDL1) have exhibited favorable long-term survival in many types of advanced-stage cancer and current approvals have to date been granted in certain tumour types irrespective of PD-L1 status.Methods: We extracted the following...
Saved in:
Main Authors: | Feiyang Zhang (Author), Guoming Chen (Author), Yixin Yin (Author), Xiaojiang Chen (Author), Runcong Nie (Author), Yingbo Chen (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2024-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Multiple cell-death patterns predict the prognosis and drug sensitivity of melanoma patients
by: Zewei Chen, et al.
Published: (2024) -
Immune Checkpoint Inhibitors in Peripheral T-Cell Lymphoma
by: Xi Chen, et al.
Published: (2022) -
First-Line Immune-Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Landscape and Future Progress
by: Zhangfeng Huang, et al.
Published: (2020) -
Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment
by: Tina Krieger, et al.
Published: (2020) -
Immune checkpoints and cancer immunotherapies: insights into newly potential receptors and ligands
by: Ali N. Kamali, et al.
Published: (2023)